The FDA has approved Boehringer Ingelheim’s Jascayd (nerandomilast) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.

The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim Jascayd (nerandomilast) tablets to treat ...

FDA approves Jascayd, the first new treatment for idiopathic pulmonary fibrosis in over a decade, significantly reducing ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...

Treatments for CF used to address symptoms, but now, modulator therapy instead addresses the faulty CFTR protein. The therapy has two mechanisms: It either opens the CFTR channel to enable salt and ...

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease ...

Cystic fibrosis (CF) is a disease that people can be born with. While there is no cure, people with CF may live well into adulthood if they receive the appropriate treatment and medical monitoring.

Elderly man using incentive spirometer for breath improvement. Helpful for pneumonia or a lung condition like chronic obstructive pulmonary disease (COPD) or cystic fibrosis TUESDAY, June 24, 2025 ...